{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/246723037"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "The dose reduction recommendations shown below are also shown as the dose of eribulin to be administered based on the strength of the ready to use solution.In the pivotal EMBRACE trial, the corresponding publication and in some other regions e.g. the US and Switzerland, the recommended dose is based on the salt form (eribulin mesilate).Patients may experience nausea or vomiting." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "medicines.org.uk" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/107128255"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/246723037"] } } }
